- Home
- CLSK vs XENE Comparison
CLSK vs XENE Comparison
Compare CLSK & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- XENE
- Stock Information
- Founded
- CLSK 1987
- XENE 1996
- Country
- CLSK United States
- XENE Canada
- Employees
- CLSK N/A
- XENE N/A
- Industry
- CLSK Finance: Consumer Services
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- XENE Health Care
- Exchange
- CLSK Nasdaq
- XENE Nasdaq
- Market Cap
- CLSK 2.7B
- XENE 2.3B
- IPO Year
- CLSK N/A
- XENE 2014
- Fundamental
- Price
- CLSK $9.00
- XENE $32.05
- Analyst Decision
- CLSK Strong Buy
- XENE Strong Buy
- Analyst Count
- CLSK 7
- XENE 11
- Target Price
- CLSK $21.33
- XENE $54.82
- AVG Volume (30 Days)
- CLSK 27.2M
- XENE 977.8K
- Earning Date
- CLSK 08-07-2025
- XENE 08-07-2025
- Dividend Yield
- CLSK N/A
- XENE N/A
- EPS Growth
- CLSK N/A
- XENE N/A
- EPS
- CLSK N/A
- XENE N/A
- Revenue
- CLSK $537,401,000.00
- XENE $7,500,000.00
- Revenue This Year
- CLSK $105.83
- XENE N/A
- Revenue Next Year
- CLSK $43.33
- XENE $253.71
- P/E Ratio
- CLSK N/A
- XENE N/A
- Revenue Growth
- CLSK 89.47
- XENE N/A
- 52 Week Low
- CLSK $6.45
- XENE $26.74
- 52 Week High
- CLSK $20.64
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- CLSK 46.89
- XENE 51.34
- Support Level
- CLSK $8.71
- XENE $31.22
- Resistance Level
- CLSK $10.35
- XENE $33.46
- Average True Range (ATR)
- CLSK 0.58
- XENE 1.28
- MACD
- CLSK -0.10
- XENE 0.27
- Stochastic Oscillator
- CLSK 30.77
- XENE 68.60
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.